Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome

详细信息    查看全文

• 作者：Yavuz Emre Şü ; kü ; r ; Batuhan Ö ; zmen ; ^{batuhanozmen@gmail.com}Author Vitae ; Elif Didem Ö ; zdemir ; Mehmet Murat Seval ; Erkan Kalafat ; Murat Sö ; nmezer ; Bü ; lent Berker ; Ruşen Aytaç ; Cem Somer Atabekoğlu
• 关键词：GnRH agonist trigger ; GnRH antagonist ; intracytoplasmic sperm injection ; leuprolide ; triptorelin
• 刊名：Reproductive BioMedicine Online
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：34
• 期：1
• 页码：5-10
• 全文大小：554 K
• 卷排序：34

文摘

Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.